These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25174440)

  • 1. Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients.
    Atzori L; Conti B; Zucca M; Pau M
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1626-30. PubMed ID: 25174440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
    Caletti C; Granata S; Tomei P; Lupo A; Zaza G
    G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinuria associated with mTOR inhibitors after kidney transplant.
    Guney M; Sahin G; Yilmaz B; Canbakan M; Gucun M; Kayatas K; Eren P; Titiz I
    Exp Clin Transplant; 2014 Dec; 12(6):539-42. PubMed ID: 25489805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
    Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
    Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus and everolimus in kidney transplantation.
    Moes DJ; Guchelaar HJ; de Fijter JW
    Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.
    Nashan B; Citterio F
    Transplantation; 2012 Sep; 94(6):547-61. PubMed ID: 22941182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
    Errasti P; Izquierdo D; Martín P; Errasti M; Slon F; Romero A; Lavilla FJ
    Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
    Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
    Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.
    Gabardi S
    Prog Transplant; 2013 Mar; 23(1):55-7. PubMed ID: 23448821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R; Lacouture M; Wu S
    Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.